Table 1 Clinical characteristics
From: Renal extramedullary hematopoiesis: interstitial and glomerular pathology
Patient | Age/gender | Renal presentation | Hematological disorder | Duration of hematologic disorder at the time of kidney biopsy (months) | Other sites of EMH | Comorbidities | Serum creatinine at presentation (mg/dl) | Proteinuria (g/24 h) | Treatment | Renal outcome (SCr, mg/dl) | Patient outcome | Duration of follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 47/M | Acute renal failure | Plasma cell myeloma | 0 | Liver | HIV, hepatitis B | 5.8 | 3 (1+ protein on UA) | Lenalidomide, bortezomib, dexamethasone | 2.8 | Deceased; respiratory failure from infection | 48 |
2 | 87/M | Acute renal failure and proteinuria | PMF | 12 | None | Hypertension, gout | 2.3 | 3.2 | Maintained on pomalidomide | 3.2 | Deceased | 24 |
3 | 61/M | Nephrotic syndrome and renal failure | PMF | 7 | Liver and spleen | DM, chronic TTP, hypertension | 1.3 | >28 | Hydroxyurea, investigational drug (analog of thalidomide) | 1.4 | Deceased | 36 |
4 | 78/M | Chronic kidney disease and nephrotic range proteinuria | PMF | Unknown | None | Unknown | 1.7 | >10 | Unknown | Unknown | Deceased | 38 |
5 | 72/M | Renal failure and proteinuria | Myeloproliferative neoplasm, NOS | 108 | Spleen | Hypertension; gout | 3.4 | 3.7 | Steroids | Unknown | Deceased | 46 |
6 | 75/M | Renal failure and perirenal mass lesion | PMF | 84 | Spleen, liver and lungs | None | 1.8 | 0.5 | Hydroxyurea | 1.3 | Deceased | 120 |
7 | 56/M | Chronic kidney disease and nephrotic range proteinuria | PMF | 180 | Spleen | None | 2.7 | >10 | Anagrelide | 2.4 | Deceased | 10 |
8 | 65/F | Acute renal failure and proteinuria | PMF | 0 | Liver and spleen | Hypertension and DM | 7.3 | Present | Unknown | Unknown | Not available | NA |
9 | 67/M | Acute renal failure and proteinuria | ET | 216 | Spleen | Hypertension, DM and gout | 2.5 | 7 | Hydroxyurea; anagrelide | 3.9 | Deceased | 5 |
10 | 82/F | Acute on chronic renal failure and proteinuria | PMF | Unknown | Unknown | Unknown | 5.6 | 14 | Unknown | Unknown | Deceased | 4 |
11 | 73/M | Renal failure and proteinuria | PMF | Unknown | Unknown | HTN | 1.6 | 11.8 | Unknown | 1.2 | Deceased | 7 |
12 | 49/F | Renal failure and proteinuria | Plasma cell myeloma | 1 | Unknown | None | 3.1 | 1.8 | Cyclophosphamide, bortezomib, dexamethasone and PBSCT | 1.2 | Persistent renal dysfunction | 10 |
13 | 66/F | Renal failure and proteinuria | PMF | 216 | Spleen | Hypertension | 1.2 | 0.6 | Hydrea, anagrelide and ruxolitinib | 1.4 | Progressive renal dysfunction | 5 |
14 | 79/F | Renal failure and proteinuria | PV | 240 | Spleen | Hypertension | 1.2 | 5.0 | Chlorambucil | NA | NA | NA |
